CytomX Therapeutics Inc. (CTMX)
NASDAQ · Healthcare
CytomX Therapeutics Inc. Operating Income 2013–2025
CytomX Therapeutics Inc. annual/quarterly operating income history and growth rate from 2013 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- CytomX Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -19.7 M, a 186.96% decrease year-over-year.
- CytomX Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -14.1 M, a 235.12% decrease year-over-year.
- CytomX Therapeutics Inc. annual operating income for 2025 was -22.4 M, a 189.47% decrease from 2024.
- CytomX Therapeutics Inc. annual operating income for 2024 was 25.0 M, a 485.49% decrease from 2023.
- CytomX Therapeutics Inc. annual operating income for 2023 was -6.5 M, a 93.60% decrease from 2022.
- CytomX Therapeutics Inc. annual operating income for 2022 was -101.3 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
CytomX Therapeutics Inc. Operating Income — FAQ
CytomX Therapeutics Inc. (CTMX) operating income over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
What is CytomX Therapeutics Inc.'s operating income?
CytomX Therapeutics Inc. (CTMX) reported operating income of -$22M for fiscal 2025.
Where can I see CTMX's operating income history?
The chart and table above show CytomX Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.